Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II

The research product, registered as a nutritional supplement (Ocoxin®, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin®-Viusid® on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin®-Viusid® it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.

• To evaluate the effect of Ocoxin®-Viusid® on the quality of life of patients.
• To evaluate the influence of Ocoxin®-Viusid® on tolerance to onco-specific therapy.
• Identify the changes that occur in the nutritional status of patients receiving the supplement.
• To evaluate the toxicity of Ocoxin®-Viusid® in combination with chemotherapy in patients with metastatic colorectal adenocarcinoma.

Inclusion Criteria:

• Patients of any sex, resident in Cuba, with an age greater than or equal to 18 years.
• Patients that meet the diagnostic criteria.
• Patients with general health according to Karnofsky ≥70%.
• Life expectancy greater than or equal to 3 months.
• Patients eligible to receive FOLFOX-IV chemotherapy.
• Patients who have signed the informed consent.
• Patients who have laboratory values in parameters that do not contraindicate the administration of chemotherapy:
• Hemoglobin ≥ 90 g / l
• Total Leukocyte Count ≥ 3.0 x 109 / L
• Absolute Neutrophil Count ≥1.5 x 109 / L
• Platelet Count ≥100 x 109 / L
• Total bilirubin values ≤ 1.5 times the upper limit of the normal range established in the institution.
• TGO and TGP values ≤2.5 times the upper limit of the normal interval established in the institution.
• Creatinine values within the normal limits of the institution.

Exclusion Criteria:

• Pregnant or lactating patients.
• Patients with known hypersensitivity to (5 Fluoracil, Folinic Acid or Oxaliplatin).
• Patients who are receiving another product under investigation.
• Patients with decompensated intercurrent diseases, including: hypertension, diabetes mellitus, ischemic heart disease, active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver damage or any other special condition that at the discretion of the doctor puts their health at risk and his life during the study or his participation in the trial.
• Patients with brain metastases.
• Patients with mental disorders that may limit adherence to the requirements of the clinical trial and may hinder the collection of information, treatment or follow-up.

It is planned to include a total of 40 patients in the study, taking into account 10% of losses.